Renal Cell Carcinoma

The FDA has approved nivolumab and hyaluronidase-nvhy for subcutaneous injection in adults with solid tumors in which nivolumab is indicated, according to a press release.

In 2024, the treatment landscape for kidney cancer evolved, with new breakthroughs in combination therapies, new challenges and an emphasis on addressing disparities in care.

WASHINGTON — In this video, Namrata Singh, MD, MSCI, discusses a presentation from ACR Convergence 2024 that examined patients with rheumatoid arthritis who develop lung cancer.

Belzutifan significantly improved PFS and objective response compared with everolimus for patients with advanced renal cell carcinoma, according to results of a randomized phase 3 trial.

The addition of nivolumab to low-dose tivozanib did not improve PFS for patients with advanced renal cell carcinoma, according to data from the agent’s manufacturer.

ORLANDO — Adults with obesity who reduce their body weight lower their odds for developing an obesity-related cancer, according to data presented at the American Diabetes Association Scientific Sessions.

Oncologic treatment of adults with various metastatic or advanced solid tumors may not improve OS and could be detrimental to quality of life, according to findings published in JAMA Oncology.

Sumanta K. Pal, MD, FASCO, expressed a mix of emotions.

Tumor mutational burden may help predict benefit of immune checkpoint inhibitor therapy for men with metastatic castration-resistant prostate cancer, according to retrospective study results.

NASHVILLE, Tenn. — Insurance status appeared associated with survival among patients with metastatic renal cell carcinoma, according to findings presented at International Kidney Cancer Symposium: North America.